Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.
Jasper Therapeutics has raised $132.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Jasper Therapeutics's investors include Citadel, Balyasny Asset Management, Samsara BioCapital, Mirador Therapeutics, Abingworth.
Jasper Therapeutics is headquartered in Redwood City, United States.
Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.
Jasper Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Jasper Therapeutics — Funding & Investors." VCBacked, July 16, 2026, https://www.vcbacked.co/company/jasper-therapeutics. Accessed November 13, 2026.
VCBacked. (2026). Jasper Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/jasper-therapeutics
{{cite web |title=Jasper Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/jasper-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Jasper Therapeutics? Request a listing update